Clinical trials: Malignant Melanoma
Skin Cancer
DermaSensor Study of Primary Care Physician Use of Elastic-Scattering Spectroscopy (ESS) on Skin Lesions Suggestive of Skin Cancer
The purpose of this study is to evaluate the clinical validity of the proprietary DermaSensor Elastic Scattering Spectroscopy (ESS) device and classifier algorithm to support assessment of skin lesions suggestive of melanoma…
- Trial name
- DERM-SUCCESS (NCT06690086)
- Testing
- Lesion biopsy, DermaSensor Device Use
- Where
- United States
- Volunteers
- 1,028 people
- Sponsor
- DermaSensor, Inc.
Intraocular Melanoma
Bone Marrow and Blood Samples From Patients With Metastatic Choroid Melanoma
RATIONALE: Studying samples of bone marrow and blood from patients with cancer may help doctors find out the extent of disease. PURPOSE: This research study is collecting bone marrow and blood samples from patients with…
- Trial name
- NCT00897624
- Testing
- gene expression analysis, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis
- Volunteers
- 15 people
- Sponsor
- Institut Curie
Solid Tumor, Melanoma
A Study of TRK-950 in Patients With Advanced Solid Tumors
Part 1 To determine the safety and tolerability of TRK-950 in patients with advanced solid tumors Part 2 To determine the safety and tolerability of TRK-950 in combination with nivolumab(NIVO) in patients with advanced solid…
- Trial name
- NCT05423262
- Testing
- TRK-950, Nivolumab
- Where
- 10 sites in Japan
- Volunteers
- 49 people
- Sponsor
- Toray Industries, Inc
Advanced Solid Tumors, Metastatic Melanoma
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
This is an open-label, 3-arm, fixed-sequence study to evaluate the effect of single and multiple oral doses of encorafenib in combination with binimetinib on the single oral dose pharmacokinetics (PK) of cytochrome P450 (CYP)…
- Trial name
- NCT03864042
- Testing
- losartan, dextromethorphan, caffeine
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 56 people
- Sponsor
- Pfizer
Head and Neck Mucosal Melanomas
A Prospective, Single-Arm, Phase II Clinical Study of Neoadjuvant Therapy With Pucotenlimab, Lenvatinib, and Temozolomide for Resectable Head and Neck Mucosal Melanoma (PLT-NAT-HNMM-II)
This study aims to conduct a prospective clinical trial investigating the use of pucotenlimab in combination with lenvatinib and temozolomide as neoadjuvant and postoperative adjuvant therapy for resectable oral and head and neck…
- Trial name
- NCT07353073
- Testing
- Preoperatively, patients will receive 2 cycles of pucotenlimab (200 mg every 3 weeks, or 3 mg/kg every 3 weeks) combined with lenvatinib (20 mg once daily) and temozolomide (150 mg/m² orally once dail
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Melanoma, Kidney Cancer
Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy
Therapy with Interleukin-2 stimulates lymphocytes in humans to become Lymphokine-activated Killer cells (LAK). This study will determine if these killer cells are able to kill certain standard cell-lines in the laboratory.
- Trial name
- LAK (NCT01068470)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Loma Linda University
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
This is a randomized, double-blind, fully controlled feeding study that will enroll melanoma patients starting standard-of-care ICB in three settings: adjuvant, neoadjuvant, and unresectable.
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage III Cutaneous Melanoma AJCC v8
- Trial name
- DIET (NCT04645680)
- Testing
- Dietary Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Renal Cancer, Melanoma
Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
The primary objective of this study will be to determine the toxicity and Maximum Tolerated Dose (MTD) of the combination of high dose aldesleukin and sorafenib in previously untreated patients with metastatic or unresectable…
- Trial name
- NCT00418496
- Testing
- Aldesleukin, Sorafenib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Melanoma
Impact of Excision Margins on Survival and Recurrence Rate in Patients With Thick Melanoma (>2mm)
Objective: To investigated the impact of the excision of melanoma 2mm≤ in thickness with 1cm surgical margins on survival of the patients compared with 2 cm surgical margins.
- Trial name
- NCT02088762
- Testing
- surgical excision
- Where
- Switzerland
- Volunteers
- 325 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Melanoma
Utility of Novel BRAF Test for Melanoma
This primary purpose of this study is to obtain blood samples from participants with both early and later stages of melanoma (Stage II/III and Stage IV).
- Trial name
- NCT01840527
- Where
- 3 sites in United States
- Volunteers
- 220 people
- Sponsor
- Massachusetts General Hospital
Melanoma
Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)
Melanoma is an immune-modulated malignancy and immune checkpoint modulators which inhibit PD-1 function (pembrolizumab, nivolumab) have demonstrated clinical efficacy as treatment for patients with stage IV melanoma.
- Trial name
- NCT03241927
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Nina Bhardwaj
Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
This is a clinical study to compare the efficacy and safety of HBI-8000 combined with nivolumab to Placebo combined with nivolumab in patients with unresectable or metastatic melanoma.
- Trial name
- NCT04674683
- Testing
- HBI-8000 in combination with nivolumab
- Where
- 139 sites in United States, Australia and 15 more
- Volunteers
- 450 people
- Sponsor
- HUYABIO International, LLC.
Glioblastoma, Melanoma Stage IV
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors.
- Conditions
- Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer
- Trial name
- NCT04478279
- Testing
- ST101, Temozolomide, Radiation
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 125 people
- Sponsor
- Sapience Therapeutics
Skin Lesions
Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging
The use of MDS to access the presence of melanoma in the skin.
- Trial name
- NCT02056522
- Where
- 2 sites in Israel
- Volunteers
- 357 people
- Sponsor
- Orlucent, Inc
Melanoma
Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec
The primary objective was to estimate the proportion of participants with detectable talimogene laherparepvec deoxyribonucleic acid (DNA) in the blood and urine at any time after administration of talimogene laherparepvec within…
- Trial name
- NCT02014441
- Testing
- Talimogene laherparepvec
- Where
- 14 sites in United States, Canada
- Volunteers
- 61 people
- Sponsor
- Amgen
Metastatic Melanoma
Safety of ADU-1604 in Adults With Metastatic Melanoma
This study is a first-in-human, open-label, multicenter, dose-escalation study designed to evaluate the safety, PK, and PD of ADU-1604 and explore initial clinical activity in adults with metastatic melanoma.
- Trial name
- NCT03674502
- Testing
- ADU-1604
- Where
- 5 sites in France, Spain
- Volunteers
- 4 people
- Sponsor
- Aduro Biotech, Inc.
Melanoma
Melanoma: Genomic Profiles, Molecular Markers and Therapeutic Implications
The goal of this study is to evaluate the genomic profiles and investigate the prevalence of germ line and pathogenic mutations in Greek population with early and metastatic melanoma and their correlation with the treatment and…
- Trial name
- NCT05119829
- Where
- Greece
- Volunteers
- 80 people
- Sponsor
- Hellenic Cooperative Oncology Group
Metastatic Melanoma, Advanced Melanoma
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
The purpose of this study is to investigate the use of ctDNA measurements to guide first-lien therapy choice for patients with advanced or metastatic melanoma. Primary endpoints include progression-free survival.
- Trial name
- NCT07504796
- Testing
- Nivolumab, Relatlimab, Ipilimumab
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- NYU Langone Health
Non-melanoma Skin Cancer
Post-market Multi-Center RETRO-Prospective Study to Assess Long-term Clinical Outcomes NMSC Patients Treated With eBx
The purpose of this retrospective-prospective study is to evaluate lesions after treatment for BCC or SCC NMSC in order to gain a better understanding of the durability of the treatment, and risk of late toxicities for this…
- Trial name
- NCT05257486
- Testing
- Xoft eBx
- Where
- 2 sites in United States
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- Xoft, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.